A. Bonjoch

Comparison of two different strategies of treatment with zoledronate in HIV‐infected patients with low bone mineral density: single dose versus two doses in 2 years

B. Clotet, E. Negredo, J. Puig, 2015, HIV medicine.

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

B. Clotet, M. Odriozola, J. Olalla, 2017, The Journal of antimicrobial chemotherapy.

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia

E. Negredo, J. Puig, B. Clotet, 2017, HIV medicine.

Increased Antiretroviral Potency by the Addition of Enfuvirtide to a Four-Drug Regimen in Antiretroviral-Naive, HIV-Infected Patients

B. Clotet, J. Martinez-Picado, L. Ruiz, 2006, Antiviral therapy.

Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study

J. Schapiro, J. Martinez-Picado, E. Negredo, 2008, HIV medicine.

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

J. De La Torre, J. Prada, S. Reus, 2018, The Journal of antimicrobial chemotherapy.